Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

[1] El-Zoghby ZM(2009)Identifying specific causes of kidney allograft loss Am J Transplant 9 527-535

[2] Stegall MD(2014)The Histology of Kidney Transplant Failure Transplantation 98 427-435

[3] Lager DJ(2018)The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials Am J Transplant 18 293-307

[4] Kremers WK(2015)Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection Nephrol Dial Transplant 30 1825-1833

[5] Amer H(2010)Determinants of long-term graft outcome in transplant glomerulopathy Transplantation 90 757-764

[6] Gloor JM(2012)Transplant glomerulopathy: clinical course and factors relating to graft survival Transplant Proc 44 2599-2600

[7] Cosio FG(2008)Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients Transplantation 86 1214-1221

[8] Naesens Maarten(2009)Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection Transplantation 87 1837-1841

[9] Kuypers Dirk R.J.(2012)Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection Transplant Proc 44 182-184

[10] De Vusser Katrien(2012)IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up Transpl Int 25 1165-1173

[1] El-Zoghby ZM(2009)Identifying specific causes of kidney allograft loss Am J Transplant 9 527-535

[2] Stegall MD(2014)The Histology of Kidney Transplant Failure Transplantation 98 427-435

[3] Lager DJ(2018)The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials Am J Transplant 18 293-307

[4] Kremers WK(2015)Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection Nephrol Dial Transplant 30 1825-1833

[5] Amer H(2010)Determinants of long-term graft outcome in transplant glomerulopathy Transplantation 90 757-764

[6] Gloor JM(2012)Transplant glomerulopathy: clinical course and factors relating to graft survival Transplant Proc 44 2599-2600

[7] Cosio FG(2008)Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients Transplantation 86 1214-1221

[8] Naesens Maarten(2009)Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection Transplantation 87 1837-1841

[9] Kuypers Dirk R.J.(2012)Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection Transplant Proc 44 182-184

[10] De Vusser Katrien(2012)IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up Transpl Int 25 1165-1173